Trastuzumab in early curative breast cancer: A target trial emulation benchmarked against two randomized clinical trials.

ABSTRACT:

Background

Benchmarking an observational analysis against a randomized trial can increase confidence in the use of observational data to complement inferences made in trials. Until now, few examples of benchmarking have been within oncology. However, benchmarking trials of a cancer treatment poses a unique set of challenges, such as defining composite outcomes like disease-free survival.

Methods and findings

We designed a target trial with a protocol as similar as possible to the B-31 and N9831 randomized trials, which estimated the effect of adjuvant trastuzumab plus chemotherapy compared with chemotherapy alone in individuals with early human epidermal growth factor receptor 2-positive breast cancer. We then carried out an observational analysis by emulating the target tri

SUBMITTER: Voelskow V 

PROVIDER: S-EPMC12303387 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature